AB Science Wins Skin Cancer Study Shortcut; Can Skip Mid-Stage Trial and Proceed to Late Stage

Reuters -- AB Science (ABS.PA) has won EU and U.S. approval immediately to begin final-stage clinical studies in advanced melanoma, skipping one trial stage and taking the French biotech's number of late-stage products to nine.